The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Initial results of a screening trial for evaluating oncogenic drivers in Japanese patients with surgically resected early-stage non-small cell lung cancer: LC-SCRUM-Advantage.
 
Yuki Matsumura
No Relationships to Disclose
 
Kiyotaka Yoh
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi sankyo; Kyowa Kirin; Lilly Japan; MSD; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim
Research Funding - Abbvie (Inst); Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Yoshitaka Zenke
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health; Johnson & Johnson/Janssen; Kyowa Kirin International; Lilly; MSD Oncology; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim
Research Funding - Amgen (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); GlaxoSmithKline (Inst); Merck Serono (Inst); MSD (Inst)
 
Shingo Kitagawa
No Relationships to Disclose
 
Joji Samejima
No Relationships to Disclose
 
Toshio Kasugai
No Relationships to Disclose
 
Hiroshi Saijo
Speakers' Bureau - AstraZeneca
 
Takafumi Hashimoto
Speakers' Bureau - Chugai Pharma; MSD
 
Ryu Kanzaki
No Relationships to Disclose
 
Ikue Kamei
No Relationships to Disclose
 
Gaku Yamamoto
No Relationships to Disclose
 
Yu Tanaka
No Relationships to Disclose
 
Hiroki Izumi
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo/UCB Japan; Lilly; Merck; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen
Research Funding - Abbvie (Inst); Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Eisai/MSD (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Tetsuya Sakai
Honoraria - Amco; AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Merck; MSD; Novartis; Olympus; Taiho Pharmaceutical
Research Funding - Amgen; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Merck
 
Eri Sugiyama
No Relationships to Disclose
 
Shigeki Umemura
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; MSD; Takeda
Research Funding - Daiichi sankyo (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)
 
Shingo Matsumoto
Honoraria - Amgen; AstraZeneca; Chugai Pharma; Lilly; Merck; Novartis
Research Funding - Chugai Pharma (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst)
 
Masahiro Tsuboi
No Relationships to Disclose
 
Koichi Goto
Honoraria - Amgen; Amoy Diagnostics; AstraZeneca Japan; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health; Janssen; Lilly Japan; Merck; Nippon Kayaku; Novartis; Ono Pharmaceutical; RIKEN GENESIS CO., LTD.; Sysmex; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - Amgen; Amgen; Bayer HealthCare Pharmaceuticals Inc.,; Bristol-Myers Squibb K.K.; DAIICHI SANKYO Co., Ltd.; GlaxoSmithKline K.K.; Guardant Health Japan Corp.; Haihe Biopharma Co., Ltd.; iTeos Therapeutics Inc.; Janssen; Lilly Japan; Novartis; Pharma Mar, S.A.; Syneos Health
Research Funding - Abbvie (Inst); Amgen (Inst); Amgen (Inst); AnHeart Therapeutics Inc. (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb K.K. (Inst); Chugai Pharma (Inst); CRAIF Inc. (Inst); DAIICHI SANKYO Co., Ltd. (Inst); Eisai (Inst); Guardant Health Asia, Middle East & Africa, Inc (Inst); HaiHe Biopharma Co., Ltd. (Inst); Ignyta (Inst); Janssen (Inst); Kyowa Kirin Co., Ltd. (Inst); Life Technologies (Inst); Lilly Japan (Inst); Loxo (Inst); Lunit (Inst); MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (Inst); Merck (Inst); Merus (Inst); MSD K.K. (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Precision Medicine Asia Co., Ltd. (Inst); RIKEN GENESIS CO., LTD. (Inst); Spectrum Pharmaceuticals (Inst); Sumitomo Pharma Co., Ltd. (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Turning Point Therapeutics (Inst)